Decibel Therapeutics, Inc. Common Stock
DBTX
DBTX: Decibel Therapeutics Inc is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders. It aims to restore and improve hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. Its lead gene therapy product candidate is DB-OTO which provides hearing to individuals born with profound hearing loss due to an OTOF deficiency. The firm's pipeline products comprise DB-ATO, AAV.103, AAV.104, AAV.201, DB-020, and Cochlear Hair Cell Regeneration.
moreShow DBTX Financials
Recent trades of DBTX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by DBTX's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Methods of otoprotection against platinum-based antineoplastic agents Jul. 04, 2023
-
Patent Title: Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems May. 30, 2023
-
Patent Title: Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent Jul. 27, 2021
-
Patent Title: Methods of otoprotection against platinum-based antineoplastic agents Oct. 27, 2020
-
Patent Title: Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent Jul. 14, 2020
Federal grants, loans, and purchases
Followers on DBTX's company Twitter account
Number of mentions of DBTX in WallStreetBets Daily Discussion
Recent insights relating to DBTX
Recent picks made for DBTX stock on CNBC
ETFs with the largest estimated holdings in DBTX
Flights by private jets registered to DBTX